Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Laurus Labs Limited Call Transcript 2021

Apr 26, 2021

62639_rns_2021-04-26_1ed5ae93-b56b-4444-b12f-006e30eb8a3a.pdf

Call Transcript

Open in viewer

Opens in your device viewer

==> picture [114 x 37] intentionally omitted <==

LAURUS LABS LIMITED

LAURUS LABS LTD. Q4 & FY21 RESULTS CONFERENCE CALL ON FRIDAY, APRIL 30, 2021 AT 11:00 AM IST

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Friday, April 30, 2021 at 11:00 am IST .

The conference call will be initiated with a brief management discussion on the Q4 & FY21 results, followed by an interactive Question & Answer session. The call will be hosted by Ambit Capital.

Details of the conference call are as follows:

For Diamond pass please Copy this URL in your browser:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7598724&linkSecurityString=1972ca58c0

Timing 11:00 am IST on Friday, April 30, 2021
Conference dial-in
Primarynumber +91 22 6280 1148
SecondaryNumber +91 22 7115 8049_Available all over India_
Singapore 800 101 2045
HongKong 800 964 448
USA 1 866 746 2133
UK 0 808 101 1573

- ENDS –

==> picture [139 x 54] intentionally omitted <==

APRIL 26, 2021

PAGE 2

==> picture [113 x 36] intentionally omitted <==

About Laurus Labs Ltd.

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UKMHRA etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. Corporate Identification No: L24239AP2005PLC047518

For further information, please contact

Vivek Kumar

Laurus Labs Limited Tel: +91 40 6659 4366 Email: [email protected]

APRIL 26, 2021